Effect of phospholipid curcumin Meriva® on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial

Giovanni Musso; Silvia Pinach; Filippo Mariano; Francesca Saba; Franco De Michieli; Luciana Framarin; Mara Berrutti; Elena Paschetta; Renato Parente; Yanina Lizet Castillo; Nicola Leone; Francesca Castellino; Maurizio Cassader; Roberto Gambino

doi:10.1097/HEP.0000000000000937

Effect of phospholipid curcumin Meriva® on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial

Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937. Online ahead of print.

Affiliations

¹ MECAU Department San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
² Department of Medical Sciences, Città della Salute e della Scienza Hospital, University of Turin, Italy.
³ Department of Nephrology, Città della Salute e della Scienza Hospital, University of Turin, Italy.
⁴ Gastroenterology Unit, HUMANITAS Gradenigo Hospital, Turin, Italy.
⁵ MECAU Department, HUMANITAS Gradenigo Hospital, Turin, Italy.
⁶ Pathology Unit, HUMANITAS Gradenigo Hospital, Turin, Italy.
⁷ Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

PMID: 38809154
DOI: 10.1097/HEP.0000000000000937

Abstract

Background aims: Nonalcoholic steatohepatitis (NASH) confers an increased liver-related and kidney morbidity. Phospholipid curcumin (Meriva ® ) is a phospholipid formulation with ameliorated systemic curcumin absorption and delivery. We assessed safety and efficacy of Meriva ® in NASH.

Approach: In this double-blind trial, 52 biopsy-proven NASH patients(71% with stage ≥F2 fibrosis, 58% with stage A2-G2/A2-G3a CKD) were randomized 1:1 to receive Meriva ® 2 g/day or placebo for 72 weeks. Primary end-point was NASH resolution with no worsening of fibrosis. Secondary end-points included: a ≥1 stage liver fibrosis improvement with no NASH worsening; regression of significant(i.e. stage≥F2) fibrosis and of chronic kidney disease(CKD); improvement in renal, glucose, lipid and inflammatory parameters. We also explored treatment effect on hepatic activation of Nuclear Factor(NF)-kB, a key proinflammatory transcription factor and a major target of curcumin.

Results: Fifty-one patients(26 on Meriva ® and 25 on placebo) completed the trial. Sixteen(62%) patients on Meriva ® vs. three(12%) patients on placebo had NASH resolution(RR=5.33[95%CI=1.76-12.13]; p=0.003). Thirteen(50%) patients on Meriva ® vs. 2(8%) patients on placebo had ≥1 stage fibrosis improvement(RR=6.50[(1.63-21.20]; p=0.008). Eleven(42%) patients on Meriva ® vs. 0(0%) on placebo had regression of significant liver fibrosis(RR=18.01[1.43-36.07]; p=0.02). Hepatic NF-kB inhibition predicted NASH resolution(AUC=0.90,95%CI=0.84-0.95) and fibrosis improvement(AUC=0.89,95%CI=0.82-0.96). Thirteen(50%) patients on Meriva ® vs. 0(0%) on placebo had CKD regression(RR=10.71[1.94-17.99)]; p=0.004). Compared with placebo, Meriva ® improved eGFR(difference in adjusted eGFR change: +3.59[2.96-4.11] mL/min/1.73 m 2 /year, p =0.009), fasting glucose(-17 mg/dL;95%CI=-22, -12), HbA1c(-0.62%;95%CI=-0.87%, -0.37%), LDL-C(-39 mg/dL; 95%CI=-45, -33), triglycerides(-36 mg/dL, 95%CI= -46, -26), HDL-C(+10 mg/dL; 95%CI=+8, +11) and inflammatory markers. Adverse events were rare, mild and evenly distributed.

Conclusion: In NASH patients, Meriva ® administration for 72 weeks was safe, well-tolerated, improved liver histology, possibly through NF-kB inhibition, kidney disease, and metabolic profile.